VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The latest updates on tafasitamab in DLBCL

Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the latest updates on the use of tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL) and ongoing clinical trials evaluating this agent. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter